Get the Stockscreener App
70.63
0.51%
-0.36
After Hours:
71.52
0.89
+1.26%
Bridgebio Pharma Inc stock is traded at $70.63, with a volume of 1.88M.
It is down -0.51% in the last 24 hours and up +30.17% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$70.99
Open:
$70.675
24h Volume:
1.88M
Relative Volume:
0.78
Market Cap:
$13.61B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-29.31
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+7.68%
1M Performance:
+30.17%
6M Performance:
+111.85%
1Y Performance:
+159.76%
1-Day Range:
$69.53
$71.65
1-Week Range:
$64.41
$71.65
52-Week Range:
$25.34
$71.65
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
70.63 | 13.68B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio to Participate in December Investor Conferences - The Manila Times
BridgeBio (Nasdaq: BBIO) to present at Piper Sandler and EvercoreISI conferences - Stock Titan
BridgeBio Pharma Insider Sold Shares Worth $1,722,224, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma CEO Kumar Neil sells $1.7m in shares By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Kumar Neil sells $1.7m in shares - Investing.com
Biotech Stock Could Turn 4-Year Peak Into Records - Finviz
BridgeBio Pharma stock hits 52-week high at 69.69 USD By Investing.com - Investing.com Australia
BridgeBio Pharma stock hits 52-week high at 69.69 USD - Investing.com India
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes - Seeking Alpha
BridgeBio Pharma (BBIO) Price Target Increased by 16.55% to 82.90 - MSN
BridgeBio Pharma Independent Director Wen-Chaun Lo Sells 62% Of Holding - simplywall.st
Will BridgeBio Pharma Inc. stock split attract more investors2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
Will BridgeBio Pharma Inc. (2CL) stock outperform value peersWall Street Watch & Low Drawdown Investment Ideas - newser.com
Will BridgeBio Pharma Inc. stock gain from lower inflationJuly 2025 Short Interest & Short-Term High Return Strategies - newser.com
Why BridgeBio Pharma Inc. (2CL) stock stays resilientMarket Volume Report & Weekly High Momentum Picks - newser.com
Can BridgeBio Pharma Inc. (2CL) stock ride next bull market cycle2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
How BridgeBio Pharma Inc. stock performs in stagflationShare Buyback & Free Daily Entry Point Trade Alerts - newser.com
Bridgebio Pharma Insider Sold Shares Worth $6,319,662, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (Nasdaq: BBIO) approves 34,199 inducement RSUs for 12 new employees - Stock Titan
Analyzing BridgeBio Pharma Inc. with risk reward ratio chartsMarket Rally & Verified Chart Pattern Signals - newser.com
How dovish Fed policy supports BridgeBio Pharma Inc. (2CL) stockWeekly Trend Summary & Technical Entry and Exit Alerts - newser.com
BridgeBio Pharma Insider Sold Shares Worth $1,125,404, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma (BBIO) president Trimarchi sells $1.12 million in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma (BBIO) president Trimarchi sells $1.12 million in stock - Investing.com India
What moving averages say about BridgeBio Pharma Inc.Weekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
BridgeBio Pharma (BIT:1BBIO) Price Target Increased by 19.13% to 72.40 - Nasdaq
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):